Please login to the form below

Not currently logged in
Email:
Password:

CAR-Ts

This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.

GSK’s myeloma drug hits target, prompting rapid filing pledge

GSK’s myeloma drug hits target, prompting rapid filing pledge

Antibody drug conjugate could challenge CAR-Ts. GlaxoSmithKline has unveiled some robust data for its multiple myeloma antibody drug conjugate, and chief scientific officer Dr Hal Barron has pledged a rapid ... Celgene and Bluebird’s CAR-T bb2121 is

Latest news

  • Oxford Biomedica taps Microsoft to progress gene therapy delivery tech Oxford Biomedica taps Microsoft to progress gene therapy delivery tech

    It’s the approach that is used in Novartis’ Kymriah, a CAR-T therapy that was approved last year for the treatment of those with relapsed or refractory large B-cell ... lymphoma. However, Novartis was a prime example of the complex manufacturing

  • Precision BioSciences to raise $100m for off the shelf CAR-Ts Precision BioSciences to raise $100m for off the shelf CAR-Ts

    Current CAR-Ts available on the market are manufactured on a patient-by-patient basis, unique to each individual. ... Unlike typical CAR-Ts, Precision BioSciences’ one-step genomic platform uses cells from healthy donors - reducing graft versus host

  • CMS proposes coverage scheme for CAR-T therapies CMS proposes coverage scheme for CAR-T therapies

    The information could then be used to decide what CAR-Ts are most beneficial to patients and should be funded in future. ... So far two CAR-Ts have reached the US market, but there are dozens more coming through the clinical and preclinical pipeline.

  • AbbVie enters BCMA race with Teneobio deal AbbVie enters BCMA race with Teneobio deal

    of CAR-Ts, they could emerge as the new standard of care, not having the complicated and expensive manufacturing process with the cell therapies, and also potentially producing fewer side-effects. ... The company says its platform comes with an added

  • CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

    Boysen adds: “CAR T-cell therapy is expensive, however the treatment is specific to each individual and could be a potential cure for some, although it is early days. ... CAR-Ts involve taking white blood cells from the patient, which are then

More from news
Approximately 9 fully matching, plus 21 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics